GLP-1RA Discontinuation Among Veterans With Type 2 Diabetes and Irritable Bowel Syndrome
Diabetes,Obesity,and CardioMetabolic CARE · 29.10.2026
DOI: 10.2337/doc26-0087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes,Obesity,and CardioMetabolic CARE, online erschienen am 29.10.2026. Verfasst von Chelsea R. Howland und 2 weiteren Autor:innen. Gefördert von: Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health, Veterans Rural Health Resource Center - Iowa City.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To examine whether coexisting irritable bowel syndrome (IBS) is associated with an increased risk of glucagon-like peptide 1 receptor agonist (GLP-1RA) discontinuation among veterans with type 2 diabetes. RESEARCH DESIGN AND METHODS Using national Veterans Health Administration administrative data (2018–2023), we identified 245,084 veterans with type 2 diabetes initiating a GLP-1RA. Two cohorts were defined: type 2 diabetes only and coexisting type 2 diabetes and IBS. The primary outcome was GLP-1RA discontinuation within 1 year of initiation. Discontinuation risk was compared using χ2 tests and Cox proportional hazards (CPH) regression, adjusting for demographics and clinical variables. RESULTS Among GLP-1RA initiators, 2,178 (0.9%) had coexisting IBS. Overall, 63,335 (24.8%) discontinued GLP-1RA therapy within 1 year. Rates of discontinuation were lower among veterans with IBS (491 of 2,178 [22.5%]) compared with those without IBS (62,844 of 242,906 [25.9%]) (P < 0.001). In an unadjusted CPH model, IBS was associated with a lower risk of discontinuation (hazard ratio [HR] 0.88, 95% CI 0.80–0.96), but the association was not statistically significant after adjustment (adjusted HR 0.93, 95% CI 0.85–1.01). Several covariates, including BMI, concurrent glucose-lowering therapy, depressive disorders, GLP-1RA type, and initiation year, were independently associated with discontinuation. CONCLUSIONS In a large national cohort of veterans with type 2 diabetes, IBS was not associated with higher GLP-1RA discontinuation risk after adjustment for demographic and clinical characteristics. These findings challenge assumptions that gastrointestinal comorbidities universally heighten GLP-1RA intolerance and suggest that IBS symptom experience or self-management may support persistence. Clinical decisions should consider patient comorbidity profiles, treatment burden, and symptom management experiences to optimize GLP-1RA continuation.
Förderung
- Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health, Veterans Rural Health Resource Center - Iowa City
Zitieren
APA
Howland, C. R., Lund, B. C., & Hadlandsmyth, K. (2026). GLP-1RA Discontinuation Among Veterans With Type 2 Diabetes and Irritable Bowel Syndrome. Diabetes,Obesity,and CardioMetabolic CARE. https://doi.org/10.2337/doc26-0087
Vancouver
Howland CR, Lund BC, Hadlandsmyth K. GLP-1RA Discontinuation Among Veterans With Type 2 Diabetes and Irritable Bowel Syndrome. Diabetes,Obesity,and CardioMetabolic CARE. 2026. doi:10.2337/doc26-0087
BibTeX
@article{Howland2026,
author = {Howland, Chelsea R. and Lund, Brian C. and Hadlandsmyth, Katherine},
title = {GLP-1RA Discontinuation Among Veterans With Type 2 Diabetes and Irritable Bowel Syndrome},
journal = {Diabetes,Obesity,and CardioMetabolic CARE},
year = {2026},
doi = {10.2337/doc26-0087}
}
EUVIMED